An article titled, “Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide,” was published in Journal of Diabetes Science and Technology by authors David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE, Gavin Hui, MD, and Saurabh Gombar, MD, PhD. Dr. Klonoff is affiliated with the Diabetes Research Institute in San Mateo, CA. Dr. Gombar, Chief Medical Officer and co-founder, and Dr. Hui are affiliated with Atropos Health.
Short Summary:
This study investigates a recent study that suggested a potential link between semaglutide and the risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). However, a subsequent analysis using a large, nationally representative dataset found no significant association between glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs, including semaglutide, and NAION after controlling for confounding factors.
Key Conclusions:
- The study concluded that the initial findings should be interpreted with caution and that further research is needed to confirm the association.
- Given the well-established benefits of GLP-1RAs for diabetes and obesity, it is premature to recommend changes in their use based solely on the initial study.
Read the full paper here
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com